What's new? Log in Free sign up

Syndax Pharmaceuticals (SNDX)

Company Profile

Company profile

Ticker

SNDX

Exchange

Website

CEO

Michael A. Metzger

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • AbbVie • Teva Pharmaceutical Industries Limited • Bausch Health Companies • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

PSI TEC HOLDINGS INC, THIRD-ORDER NANOTECHNOLOGIES INC, THIRD-ORDER NANOTECHNOLOIES INC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Syndax Securities Corporation • Syndax Europe B.V. ...

SNDX stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$39.50

Low target

$35.00

High target

$44.00

Latest filings (excl ownership)

View all

Quarterly report

3 Nov 25

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

Quarterly report

4 Aug 25

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

Departure of Directors or Certain Officers

Departure of Directors or Certain Officers

Quarterly report

5 May 25

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

Annual report to shareholders

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Keith A. Goldan

Michael A Metzger

Notice of proposed sale of securities

Dennis Podlesak

Syndax Pharmaceuticals Inc

Notice of proposed sale of securities

Syndax Pharmaceuticals Inc

Notice of proposed sale of securities

Beneficial ownership report (amended)

Keith A. Goldan

Financial summary

Financial statements Chart SNDX financial data

Quarter (USD)	Sep 25	Jun 25	Mar 25	Dec 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	117.03 mm	117.03 mm	117.03 mm	117.03 mm	117.03 mm	117.03 mm
Cash burn (monthly)	(no burn)	1.35 mm	19.14 mm	25.58 mm	23.51 mm	25.91 mm
Cash used (since last report)	n/a	3.12 mm	44.15 mm	58.99 mm	54.23 mm	59.76 mm
Cash remaining	n/a	113.91 mm	72.87 mm	58.03 mm	62.79 mm	57.27 mm
Runway (months of cash)	n/a	84.3	3.8	2.3	2.7	2.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

SNDX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	221	215	+2.8%
Opened positions	38	39	-2.6%
Closed positions	32	24	+33.3%
Increased positions	89	84	+6.0%
Reduced positions	60	60	–

13F shares	Current	Prev Q	Change
Total value	1.26 tn	1.67 tn	-24.4%
Total shares	103.25 mm	94.19 mm	+9.6%
Total puts	542.70 k	692.20 k	-21.6%
Total calls	1.39 mm	1.07 mm	+29.5%
Total put/call ratio	0.4	0.6	-39.5%

Largest owners	Shares	Value	Change
BlackRock	9.03 mm	$119.43 bn	+9.6%
Kynam Capital Management	8.52 mm	$112.63 bn	+45.8%
GS The Goldman Sachs Group, Inc.	5.95 mm	$78.67 bn	+269.1%
MS Morgan Stanley	5.31 mm	$70.24 bn	+498.9%
Vanguard	4.88 mm	$64.54 bn	-0.1%
Wellington Management	4.23 mm	$55.98 bn	-15.1%
STT State Street	3.92 mm	$51.79 bn	+3.9%
StemPoint Capital	2.87 mm	$37.98 bn	+65.9%
Access Industries	2.60 mm	$41.19 mm	0.0%
Soleus Capital Management	2.49 mm	$32.94 bn	+128.4%

Largest transactions	Shares	Bought/sold	Change
MS Morgan Stanley	5.31 mm	+4.43 mm	+498.9%
GS The Goldman Sachs Group, Inc.	5.95 mm	+4.34 mm	+269.1%
Eversept Partners	343.40 k	-3.76 mm	-91.6%
Kynam Capital Management	8.52 mm	+2.68 mm	+45.8%
Orbimed Advisors	0.00	-1.93 mm	EXIT
Avoro Capital Advisors	2.28 mm	-1.61 mm	-41.5%
Assenagon Asset Management	2.06 mm	+1.60 mm	+343.0%
Soleus Capital Management	2.49 mm	+1.40 mm	+128.4%
StemPoint Capital	2.87 mm	+1.14 mm	+65.9%
Citadel Advisors	1.09 mm	+1.06 mm	+3103.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SNDX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Dec 25	Goldan Keith A.	Common Stock	Gift	Dispose G	No	No	0	1,224	0.00	92,452
8 Sep 25	Metzger Michael A	Common Stock	Sell	Dispose S	No	Yes	16.4139	157,307	2.58 mm	298,661
8 Sep 25	Metzger Michael A	Common Stock	Option exercise	Acquire M	No	No	10.9	157,307	1.71 mm	455,968
8 Sep 25	Metzger Michael A	Stock options Common Stock	Option exercise	Acquire M	No	No	10.9	157,307	1.71 mm	0
18 Aug 25	Dennis Podlesak	Common Stock	Sell	Dispose S	No	Yes	15.8422	19,200	304.17 k	191,763
18 Aug 25	Dennis Podlesak	Common Stock	Option exercise	Acquire M	No	No	7.2	19,200	138.24 k	210,963
18 Aug 25	Dennis Podlesak	Stock Options Common Stock	Option exercise	Dispose M	No	No	7.2	19,200	138.24 k	0
15 Aug 25	Dennis Podlesak	Common Stock	Sell	Dispose S	No	Yes	15.5421	19,200	298.41 k	191,763
15 Aug 25	Dennis Podlesak	Common Stock	Option exercise	Acquire M	No	No	7.2	19,200	138.24 k	210,963
15 Aug 25	Dennis Podlesak	Stock Options Common Stock	Option exercise	Dispose M	No	No	7.2	4,800	34.56 k	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Syndax Presents Multiple Revuforj Revumenib Abstracts At ASH 2025 Supporting Menin Inhibition Leadership Across The Acute Leukemia Continuum

– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts ––

Syndax Pharma Highlights Key Revuforj Presentations Spanning Acute Leukemia Treatment Continuum Presented At ASH Annual Meeting

– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts ––

Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $35

Barclays analyst Etzer Darout maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Overweight and raises the price target from $22 to $35.

JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $33

UBS Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $38

Press releases

From Benzinga Pro

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts – –

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

– First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation – – Second approved indication for Revuforj in less than one year

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2025 the Company

Syndax's Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.